Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05157672
EARLY_PHASE1

Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon

Sponsor: Washington State University

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate a well-characterized, commercially available cinnamon dietary supplement as a precipitant of pharmacokinetic interactions with cytochrome P450 (CYP) 2A6 drug substrates in healthy volunteers. Nicotine gum will be used as the CYP2A6 probe drug (i.e., positive control) and letrozole as a high-impact object drug. Results will be used to inform future research on the potential use of cinnamon as a smoking cessation agent, as well as the clinical impact on pharmacotherapeutic regimens involving letrozole in cancer patients.

Key Details

Gender

All

Age Range

18 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2021-12-14

Completion Date

2024-08-31

Last Updated

2026-08-24

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

Cinnamon (2 g)

oral capsules, 2 g

DRUG

Nicotine gum (2.5 mg)

gum, 2.5 mg

DRUG

Letrozole (2.5 mg)

tablet, 2.5 mg

Locations (1)

Washington State University College of Pharmacy and Pharmaceutical Sciences

Spokane, Washington, United States